DUBLIN, November 26, 2021 / PRNewswire / – The report “Global Implantable Drug Delivery Device Market (2021-2026) by Product, Type, Technology, Application, End User, Geography, Competition Analysis and the Impact of Covid-19 with Ansoff Analysis” has been added to ResearchAndMarkets.com’s offer.
The global market for implantable drug delivery devices is estimated to be USD 18.35 billion in 2021 and is expected to reach USD 28.82 billion in 2026, growing by a CAGR of 9.45%.
The growth of the implantable drug market is driven by factors such as the growing incidence of chronic disease, the growing awareness among people about implantable drug delivery devices, increasing demand for contraceptives and intervention from government and healthcare organizations to ensure high patient safety standards. In addition, the growing awareness of the availability of high quality products and safer products, the latest advances in medicine administration techniques and rapidly increasing research and development with a view to launching new products and eliminating existing problems are expected to boost growth potential in the coming years.
However, the chances of implanted device failures, strict government regulations and policies and the high cost of devices are expected to limit market growth in the expected period.
The global market for implantable drug delivery devices is further segmented based on product, type, technology, application, end user and geography.
By product, the market is classified into contraceptive implants, spinal implants, brachytherapy seeds, drug eluting stents, bioabsorbable stents, intraocular implants, infusion pumps and others. Among all, the Drug-Eluing Stents segment is considered to have the highest market share in the forecast period.
By type, the market is classified as biodegradable and non-biodegradable. Among the two, the non-biodegradable segment is estimated to have the highest market share in the forecast period.
By technology, the market is classified as diffusion, osmotic and magnetic. Among all, the Diffusion segment is estimated to have the highest market share in the forecast period.
Upon application, the market is classified as ophthalmology, cardiology, obstetrics and gynecology, diabetes, oncology, autoimmune diseases and others. Among all, the cardiovascular segment is estimated to have the highest market share in the forecast period.
By end users, the market is classified as hospitals, outpatient surgical centers and others. Among all, the Hospital segment is assessed to have the highest market share in the forecast period.
By geography, North America expected to lead the market.
The FDA approves application for Roches Port Delivery System with ranibizumab (PDS) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD). If approved, PDS will be the first and only continuous-delivery eye implant to offer people living with nAMD an alternative to frequent eye injections – June 24, 2021.
2. Siemens Healthineers acquired Varian, strengthening its position as a holistic partner in the healthcare sector -15. April 202
Highlights of the report:
A complete analysis of the market, including the parent industry
Important market dynamics and trends
Historical, current and expected size of the market based on value and volume
Market shares and strategies for key players
Recommendations for companies to strengthen their foothold in the market
Key topics covered:
1 Report description
2 Research methodology
4 Market influencers
4.1.1 Increasing prevalence of chronic diseases
4.1.2 Increasing demand for minimally invasive drug delivery devices
4.2.1 Strict government regulations
4.2.2 High unit costs
4.3.1 Collaborative activities between key actors
4.4.1 Product recall
5 Market analysis
5.1 Regulation scenario
5.2 Porter’s Five Forces Analysis
5.3 Effects on COVID-19
5.4 Ansoff matrix analysis
6 Global market for implantable drug delivery devices, by product
6.2 Contraceptive implants
6.3 Spinal implants
6.4 Brachytherapy seeds
6.5 Stent that elutes drugs
6.6 Bioabsorbable stents
6.7 Intraocular implants
6.8 Infusion pumps
7 Global market for implantable drug delivery devices, by type
Global market for implantable drug delivery devices, by technology
9 Global market for implantable drug delivery devices, upon application
9.4 Obstetrics and gynecology
9.7 Autoimmune diseases9.8 Others
10 other Global market for implantable drug delivery devices, by end user
10.3 Outpatient surgical centers
11 Global market for implantable drug delivery devices, by geography
12 Competitive landscape
12.1 Competition Quadrant
12.2 Market share analysis
12.3 Strategic initiatives
12.3.1 M& A and Investments
12.3.2 Partnerships and collaborations
12.3.3 Product development and improvements
13 Company Profiles
13.1 Abbott Laboratories
13.2 AbbVie Inc
13.3 Allergan Inc
13.4 Alcon Inc.
13.5 Bayer AG
13.6 Bausch and Lomb Incorporated
13.7 Biotronik, Inc.
13.8 Boston Scientific Corporation
13.9 DSM Biomedical
13.10 Delpor Inc.
13.11 Medtronic Plc.
13.12 Merck & co., Inc.
13.13 Freudenberg Medical, LLC
13.16 Siemens Healthineers
13.17 Theradaptive, Inc.
13.18 Cut ENT
13.19 Nanomedical Systems, Inc.
13.20 Intarcia Therapeutics
13.21 Teleflex Incorporated
13.22 Terumo Corporation
13.23 Alimera Sciences
13.24 Eyepoint Pharmaceuticals
13.25 Delpor Inc.
13.26 3M company
For more information on this report, visit https://www.researchandmarkets.com/r/xlibzk
Research and markets
Laura Wood, Senior Manager
For EST office hours Call + 1-917-300-0470
For US / CAN toll free call 1-800-526-8630
For GMT office hours Call + 353-1-416-8900
US Fax: 646-607-1904
Fax (outside the US): + 353-1-481-1716
See original content: https://www.prnewswire.com/news-releases/global-18-35-bn-implantable-drug-delivery-device-market-to-2026-rising-awareness-on-the-availability- of-high-quality-and-safer-products-301432358.html
SOURCE Research and markets